Form 4: Zivo Bioscience Director Acquires Stock Options

Zivo Bioscience director and 10% owner Laith L. Yaldoo acquired 926 nonstatutory stock options in lieu of retainer fees.

Summary

• Laith L. Yaldoo, a Director and 10% Owner of Zivo Bioscience, Inc. (ZIVO), acquired 926 nonstatutory stock options.
• The transaction occurred on October 2, 2025.
• These options were granted under the 2024 Equity Incentive Plan for Non-Employee Directors.
• The options were issued in lieu of retainer fees totaling $9,452.05.
• Each option has an exercise price of $12.03 and allows the purchase of one share of common stock.
• The options become exercisable on October 2, 2025, and expire on October 2, 2035.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director in lieu of cash retainer fees is generally viewed positively as it aligns the director's interests with long-term shareholder value, indicating confidence in the company's future.

Positives

• Issuance of stock options to a director aligns management incentives with shareholder interests.
• The director's decision to take options in lieu of cash retainer fees demonstrates confidence in the company's future performance.

Future Outlook

This filing is a report of an insider transaction and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $9,452.05.

Industry Context

This Form 4 filing details a standard insider transaction involving director compensation through equity. It does not provide sufficient information to analyze broader industry trends or competitive positioning.

Comparison to Industry Standards

• This filing is a standard Form 4 report, which is a regulatory requirement for reporting insider transactions. It does not contain performance metrics or operational results that can be directly compared to industry benchmarks or specific comparable companies.

Corporate Governance

Related Party Transactions

• Issuance of 926 nonstatutory stock options to Director Laith L. Yaldoo in lieu of $9,452.05 in retainer fees, under the 2024 Equity Incentive Plan for Non-Employee Directors.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with long-term shareholder value.
• Management/Directors: Director received equity compensation, aligning personal financial interests with company performance.

Key Dates

Recommendation

The acquisition of stock options by a director and 10% owner in lieu of cash compensation suggests confidence in the company's future prospects, which is a positive signal. However, this single transaction report does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further comprehensive financial disclosures to make a more informed decision.

Keywords

Zivo Bioscience, ZIVO, Form 4, Insider Trading, Stock Options, Equity Incentive Plan, Director Compensation, Laith L. Yaldoo